- Ibezapolstat, the first of a novel class of antibiotics, DNA polymerase IIIC inhibitors, is currently commencing a Phase 2b clinical trial in patients with CDI - Using samples from Phase 1 healthy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback